8-K: Akebia Updates Vafseo Commercials, Advances Rare Kidney Pipeline

Akebia Therapeutics announced key corporate updates for its Vafseo commercial business and provided an outlook on upcoming milestones for its mid-stage rare kidney disease pipeline, including expected Q4 2025 Vafseo net product revenue.

Summary

• Vafseo commercial business updates include broad prescribing access for approximately 275,000 dialysis patients and ongoing pilots at the top 5 dialysis organizations.
• Enrollment is complete in VOICE, a large Phase IV trial of over 2,100 patients evaluating Vafseo against standard-of-care ESAs, with topline results expected in early 2027.
• Approximately 350 patients are enrolled in VOCAL, a Phase IV trial evaluating Vafseo TIW dosing, with data expected in Q4 2026.
• Underlying patient dosing demand for Vafseo in Q4 2025 was estimated between $10.5 million and $11.5 million.
• Q4 2025 Vafseo net product revenue is expected to be in the range of $5 million to $6 million, impacted by a $4.5-$5 million decrease in channel inventory due to a new observed dosing protocol at U.S. Renal Care (USRC).
• Revenue growth is expected to resume in Q1 2026 from increased patient access and anticipated improvement in adherence and compliance.
• The rare kidney disease pipeline is progressing, with the first patient dosed in the Praliciguat Phase 2 clinical trial for Focal Segmental Glomerulosclerosis (FSGS) in December 2025.
• An open-label Phase 2 rare kidney disease basket study for AKB-097 (a complement inhibitor) is planned to begin in 2H 2026, targeting IgA Nephropathy (IgAN), Lupus Nephritis (LN), and C3 Glomerulopathy (C3G), with initial data expected in 2027.
• AKB-9090, a HIF-PH inhibitor, is entering Phase 1 for acute kidney injury associated with cardiac surgery in 1H 2026.

Sentiment

Score: 6

Explanation: While Q4 revenue was disappointing due to inventory adjustments, the underlying demand for Vafseo is strong, and the company has a robust pipeline with multiple upcoming milestones in rare kidney diseases, supported by a solid cash position. The short-term revenue dip is offset by long-term growth potential and pipeline progress.

Positives

• Secured broad prescribing access for Vafseo, encompassing approximately 275,000 dialysis patients, which is expected to facilitate additional demand in 2026.
• Improved first refill adherence rates at USRC centers from 75% in the first 9 months of 2025 to 91% in Q4 2025 due to the implementation of a new in-center observed dosing protocol.
• Significant progress in the mid-stage rare kidney disease pipeline, including the first patient dosed in the Praliciguat Phase 2 trial and the planned initiation of the AKB-097 Phase 2 basket study in 2H 2026.
• Completed enrollment in the VOICE Phase IV trial (over 2,100 patients) with topline results expected early 2027, which has the potential to establish Vafseo as a standard of care.
• A post-hoc analysis of the Phase 3 INNO2VATE trials demonstrated favorable and statistically significant effects of Vafseo relative to darbepoetin alfa on the hierarchical composite endpoint of death or hospitalization.
• The company maintains a solid financial position with $166 million in cash & cash equivalents as of September 30, 2025.

Negatives

• Q4 2025 Vafseo net product revenue is expected to be $5-$6 million, which is significantly lower than the underlying patient dosing demand of $10.5-$11.5 million.
• A $4.5-$5 million decrease in channel inventory in Q4 2025, attributed to a new in-center observed dosing protocol at USRC, negatively impacted reported revenue.
• Fewer patient starts at USRC centers and a decrease in average dose levels at centers that shifted to the observed dosing protocol contributed to the lower Q4 revenue.

Risks

• VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE), death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access, especially if hemoglobin levels rise greater than 1 g/dL over 2 weeks or target levels exceed 11 g/dL.
• Hepatotoxicity, including hepatocellular injury, elevated serum ALT, AST, and bilirubin levels, has been reported in less than 1% of patients treated with VAFSEO.
• Worsening of hypertension, including serious cases and hypertensive crisis, was reported in 14% of VAFSEO patients.
• Seizures occurred in 1.6% of VAFSEO patients.
• Gastrointestinal (GI) erosion, including serious GI bleeding, occurred in 6.4% of VAFSEO patients.
• The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis, and its use is not recommended in this setting due to increased risks observed in clinical trials.
• VAFSEO has not been studied and is not recommended in patients with active malignancies.
• Actual results, performance, or experience may differ materially from forward-looking statements due to various risks, including the potential therapeutic benefits, safety profile, and effectiveness of Vafseo and development candidates.
• Risks associated with the ability to initiate and enroll patients in clinical trials and decisions made by health authorities (e.g., FDA) with respect to regulatory filings.
• Uncertainty regarding the potential demand, market acceptance, coverage, and reimbursement for Vafseo, including the competitive landscape and timing of generic entrants.
• Risks related to the ability to attract and retain qualified personnel, achieve and maintain profitability, and manage operating expenses.
• Manufacturing, supply chain, and quality matters, including any recalls, write-downs, impairments, or other related consequences.
• Potential for early termination of any of Akebia's collaborations.
• Changes in the geopolitical environment and uncertainty surrounding U.S. trade policy on tariffs.

Future Outlook

Akebia expects increased demand for Vafseo in 2026 as existing customers accelerate adoption and new customers operationalize protocols, leading to revenue growth resuming in Q1 2026. The company aims to establish Vafseo as the standard of care for anemia due to CKD in dialysis, supported by ongoing clinical trials (VOICE, VOCAL). The mid-stage rare kidney disease pipeline, including Praliciguat and AKB-097, is expected to generate initial data in 2027, with AKB-9090 entering Phase 1 in 1H 2026.

Management Comments

• We enter 2026 in a solid financial position and expect increased demand for Vafseo as we believe existing customers will accelerate adoption of the product and new customers will operationalize Vafseo protocols within their organizations.
• We continue to generate post-marketing Vafseo clinical data that will support our goal to make Vafseo standard of care to treat anemia due to chronic kidney disease (CKD) in dialysis.
• Our revenue-generating products are the engine driving advancement of our mid-stage pipeline, which, along with continued adoption of Vafseo, we believe can drive significant shareholder value this year and beyond.

Industry Context

Akebia operates in the significant market for anemia due to CKD in dialysis, estimated at $1 billion, where Vafseo competes with established erythropoietin stimulating agents (ESAs). The company is also expanding into the rare kidney disease space (FSGS, IgAN, LN, C3G) with pipeline candidates like Praliciguat and AKB-097, addressing unmet needs where specific treatments are lacking. The focus on tissue-targeted complement inhibition (AKB-097) represents a differentiated approach compared to systemic inhibitors.

Comparison to Industry Standards

• Vafseo is positioned against standard-of-care erythropoietin stimulating agents (ESAs) in the treatment of anemia due to CKD in dialysis, a market estimated at $1 billion.
• The VOICE Phase IV trial is evaluating Vafseo TIW against standard-of-care ESAs using a hierarchical composite endpoint of all-cause mortality and all-cause hospitalization, with results expected early 2027.
• A post-hoc analysis of the Phase 3 INNO2VATE trials demonstrated favorable and statistically significant effects of Vafseo relative to the ESA darbepoetin alfa on the hierarchical composite endpoint of death or hospitalization.
• Praliciguat is being developed for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease affecting approximately 40,000 people in the U.S. and 220,000 worldwide, for which no treatments are specifically indicated, with current treatments including steroids, immunosuppressives, and antihypertensives.
• AKB-097 is a next-generation tissue-targeted complement inhibitor, differentiating itself from systemic complement inhibitors by aiming for enhanced activity at the site of destruction with an improved risk/benefit profile and reduced treatment burden.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value from Vafseo adoption and pipeline advancements, but short-term revenue dip may cause concern.
• Patients: Development of new therapies for rare kidney diseases (FSGS, IgAN, LN, C3G, AKI) offers hope for unmet medical needs. Vafseo aims to become standard of care for anemia in dialysis patients.
• Employees: Continued R&D and commercial activities suggest stable employment and growth opportunities.
• Customers (Dialysis Organizations): Implementation of new dosing protocols and increased access to Vafseo.

Next Steps

• Resume Vafseo revenue growth in Q1 2026 from increased patient access and anticipated improvement in adherence and compliance.
• Generate post-marketing Vafseo clinical data to support its goal of becoming standard of care.
• Publication of win-odds analysis of INNO2VATE data expected.
• Initiate AKB-9090 Phase 1 trial in 1H 2026.
• Initiate AKB-097 Phase 2 rare kidney disease basket study in 2H 2026.
• Report VOCAL top-line data in Q4 2026.
• Report VOICE top-line data in early 2027.
• Generate initial data from AKB-097 study in 2027.
• Report AKB-9090 Phase 1 top-line data in Q1 2027.
• Assess the use of Praliciguat in other rare podocytopathies.

Key Dates

Recommendation

While the Q4 2025 Vafseo net product revenue is lower than expected due to a one-time inventory adjustment, the underlying patient demand remains strong, and adherence rates have improved with new protocols. The company has a robust pipeline with multiple significant milestones anticipated in 2026 and 2027, particularly in rare kidney diseases, which could drive future growth. The solid cash position provides stability. However, the immediate revenue miss and the inherent risks associated with clinical trials and commercialization warrant a "hold" rather than a "buy" until the Q1 2026 revenue rebound and pipeline data materialize.

Keywords

Akebia Therapeutics, Vafseo, vadadustat, kidney disease, anemia, CKD, dialysis, biopharmaceutical, Praliciguat, FSGS, AKB-097, IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy, AKB-9090, acute kidney injury, HIF-PH inhibitor, sGC stimulator, complement inhibitor, clinical trials, Phase 2, Phase 4, financial results, corporate update, NASDAQ: AKBA